Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals

AIDS

Volumn 28, Issue 8, 2014, Pages 1171-1179

  Knudsen, Andreas ^a   Katzenstein, Terese L ^b   Benfield, Thomas ^a   Jørgensen, Niklas R ^a   Kronborg, Gitte ^a   Gerstoft, Jan ^b   Obel, Niels ^b   Kjær, Andreas ^a   Lebech, Anne Mette ^a  

^a Mental Health Center Glostrup   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Biomarkers; Case control study; Hiv 1; Myocardial infarction; Plasminogen activator inhibitor 1

Indexed keywords

ABACAVIR; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GELATINASE B; INDINAVIR; LOPINAVIR; MYELOPEROXIDASE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA DIRECTED DNA POLYMERASE INHIBITOR; SOLUBLE ENDOTHELIAL SELECTIN; SOLUBLE INTERCELLULAR ADHESION MOLECULE 1; SOLUBLE VASCULAR CELL ADHESION MOLECULE 1; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; PEROXIDASE; SELECTIN; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGE; ANTIVIRAL THERAPY; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISEASE DURATION; ENZYME BLOOD LEVEL; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1 BLOOD LEVEL; PREDICTIVE VALUE; PRIORITY JOURNAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX RATIO; SMOKING; VIRUS LOAD; BLOOD; COMPLICATION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIAL INFARCTION; PEROXIDASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SELECTINS; VASCULAR CELL ADHESION MOLECULE-1; VIRAL LOAD;

EID: 84927566232     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000247     Document Type: Article

References (47)

1. Freiberg MSCC. HIV infection and the risk of acute myocardial infarction. J Am Med Assoc Intern Med 2013; 173:614-622.
2. Hasse B, Ledergerber B, Furrer H, Battegay M, Hirschel B, Cavassini M, et al. Morbidity and aging in HIV-infected persons: The Swiss HIV cohort study. Clin Infect Dis Off Publ Infect Dis Soc Am 2011; 53:1130-1139.
3. Collaboration TATC. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50: 1387-1396.
4. Kristoffersen US, Lebech A-M, Wiinberg N, Petersen CL, Hasbak P, Gutte H, et al. Silent ischemic heart disease and pericardial fat volume in HIV-infected patients: A case-control myocardial perfusion scintigraphy study. PLoS One 2013; 8:e72066.
5. Savès M, Chêne G, Ducimetière P, Leport C, Moal GL, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003; 37:292-298.
6. Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
7. Baker JV, Lundgren JD. Cardiovascular implications from untreated human immunodeficiency virus infection. Eur Heart J 2011; 32:945-951.
8. Hsue PY, Scherzer R, Hunt PW, Schnell A, Bolger AF, Kalapus SC, et al. Carotid intima-media thickness progression in HIV-infected adults occurs preferentially at the carotid bifurcation and is predicted by inflammation. J Am Heart Assoc Cardiovasc Cerebrovasc Dis 2012; 1:doi: 10.1161/JAHA.111.000422.
9. Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De-Wit S, et al. Inflammation, coagulation and cardiovascular disease in HIV-infected individuals. PLoS One 2012; 7:e44454.
10. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, et al. Markers of inflammation and cardiovascular disease application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003; 107:499-511.
11. Kristoffersen U, Kofoed K, Kronborg G, Giger A, Kjaer A, Lebech A. Reduction in circulating markers of endothelial dysfunction in HIV-infected patients during antiretroviral therapy. HIV Med 2009; 10:79-87.
12. D'Agostino RB. Cardiovascular risk estimation in 2012: lessons learned and applicability to the HIV population. J Infect Dis 2012; 205:S362-S367.
13. Parra S, Coll B, Aragonés G, Marsillach J, Beltrán R, Rull A, et al. Nonconcordance between subclinical atherosclerosis and the calculated Framingham risk score in HIV-infected patients: relationships with serum markers of oxidation and inflammation. HIV Med 2010; 11:225-231.
14. Knudsen A, Møller HJ, Katzenstein TL, Gerstoft J, Obel N, Kronborg G, et al. Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: A nested case-control study. BMC Infect Dis 2013; 13:230.
15. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011; 39:30-33.
16. Obel N, Engsig FN, Rasmussen LD, Larsen MV, Omland LH, Sørensen HT. Cohort profile: The Danish HIV Cohort study. Int J Epidemiol 2009; 38:1202-1206.
17. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force on standardization of clinical nomenclature. Nomenclature and criteria for diagnosis of ischemic heart disease. Circulation 1979; 59: 607-609.
18. Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
19. Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, Wit SD, et al. Predicting the risk of cardiovascular disease in HIVinfected patients: The Data collection on Adverse Effects of Anti-HIV Drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17:491-501.
20. Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 2000; 342:1792-1801.
21. Thögersen AM, Jansson J-H, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-2247.
22. Collet JP, Montalescot G, Vicaut E, Ankri A, Walylo F, Lesty C, et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003; 108:391-394.
23. Ford ES, Greenwald JH, Richterman AG, Rupert A, Dutcher L, Badralmaa Y, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection. AIDS 2010; 24:1509-1517.
24. O'Brien M, Montenont EM, Hu L, Nardi MA, Valdes VB, Merolla MB, et al. Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: A pilot study [miscellaneous article]. J Acquir Immune Defic Syndr 2013; 1:2013; 63:280-288.
25. Lieb W, Larson MG, Benjamin EJ, Yin X, Tofler GH, Selhub J, et al. Multimarker approach to evaluate correlates of vascular stiffness the Framingham Heart Study. Circulation 2009; 119:37-43.
26. Gresele P, Falcinelli E, Sebastiano M, Baldelli F. Endothelial and platelet function alterations in HIV-infected patients. Thromb Res 2012; 129:301-308.
27. Duprez DA, Kuller LH, Tracy R, Otvos J, Cooper DA, Hoy J, et al. Lipoprotein particle subclasses, cardiovascular disease and HIV infection. Atherosclerosis 2009; 207:524-529.
28. Baker J, Ayenew W, Quick H, Hullsiek KH, Tracy R, Henry K, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis 2010; 201:285-292.
29. Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003; 289:2978-2982.
30. Cotter AG, Satchell CS, O'Halloran JA, Feeney ER, Sabin CA, Mallon PW. High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients. AIDS 2011; 25: 867-869.
31. Riddler SA, Li X, Otvos J, Post W, Palella F, Kingsley L, et al. Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2008; 48:281-288.
32. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant metaanalysis. Lancet 2010; 375:132-140.
33. Pearson TA, Bazzarre TL, Daniels SR, Fair JM, Fortmann SP, Franklin BA, et al. American Heart Association guide for improving cardiovascular health at the community level: A statement for public health practitioners, healthcare providers, and health policy makers from the American Heart Association Expert Panel on Population and Prevention Science. Circulation 2003; 107:645-651.
34. Triant VA, Meigs JB, Grinspoon SK. Association of C-reactive protein and HIV infection with acute myocardial infarction. J Acquir Immune Defic Syndr 2009; 51:268-273.
35. Neuhaus J, Jacobs DR, Baker JV, Calmy A, Duprez D, La-Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010; 201:1788-1795.
36. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med 2008; 359:2195-2207.
37. De-Luca A, de-Gaetano-Donati K, Colafigli M, Cozzi-Lepri A, De-Curtis A, Gori A, et al. The association of high-sensitivity C-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: A nested case-control study. BMC Infect Dis 2013; 13:414.
38. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352:1685-1695.
39. Hwang SJ, Ballantyne CM, Sharrett AR, Smith LC, Davis CE, Gotto AM, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: The Atherosclerosis Risk In Communities (ARIC) study. Circulation 1997; 96:4219-4225.
40. Gross MD, Bielinski SJ, Suarez-Lopez JR, Reiner AP, Bailey K, Thyagarajan B, et al. Circulating soluble intercellular adhesion molecule 1 and subclinical atherosclerosis: The Coronary Artery Risk Development in Young Adults Study. Clin Chem 2012; 58:411-420.
41. Rohde LE, Lee RT, Rivero J, Jamacochian M, Arroyo LH, Briggs W, et al. Circulating cell adhesion molecules are correlated with ultrasound-based assessment of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1998; 18:1765-1770.
42. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998; 351:88-92.
43. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104: 1336-1342.
44. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585.
45. Zhang RBM. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286:2136-2142.
46. Rosito GA, D'Agostino RB, Massaro J, Lipinska I, Mittleman MA, Sutherland P, et al. Association between obesity and a prothrombotic state: The Framingham Offspring Study. Thromb Haemost 2004; 91:683-689.
47. Matthan NR, Ip B, Resteghini N, Ausman LM, Lichtenstein AH. Long-termfatty acid stability in human serum cholesteryl ester, triglyceride, and phospholipid fractions. J Lipid Res 2010; 51:2826-2832.